Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Nat Commun · 2026 · PMC13230698 · PMID 41935063

Europe PMC DOI

hedged sentence

0.2730

closest p · 5.5× alpha

0.2730

boldest claim

The sentences

did not reach statistical significancep = 0.273not close (p > 0.1)

Although patients with immune-mediated adverse events (imAEs) had numerically lower hazard ratios (HR) for both PFS and OS, these associations did not reach statistical significance when analysed as time-dependent variables (PFS: HR = 0.75, 95% CI: 0.45–1.25, p = 0.273; OS: HR = 0.61, 95% CI: 0.34–1.10, p = 0.103).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.